Efficacy of Structured Progressive Training Exercise on Muscle Strength of Patients With Rheumatoid Arthritis (RA)

March 26, 2026 updated by: Mohammed Hakim Shamran Al-Hchaim, Kufa University

This study aims to find out if a specific exercise program helps patients with Rheumatoid Arthritis (RA). RA is a chronic autoimmune disease that causes pain, weakness, and reduced function in the joints and muscles. While medication is common, exercise is also important for management.

The study will test a program called "Progressive Resistance Training." About 118 adult patients with RA at AL-Najaf Teaching Hospital will participate. They will be divided into two groups. One group will perform specific resistance exercises for six weeks, while the other group will continue their usual care without this specific training.

The researchers will measure muscle strength, cardiovascular function, and energy levels before and after the six-week program. The goal is to determine if this exercise improves muscle strength and helps patients perform daily activities more efficiently. The study hopes to show that resistance training is a safe and effective way to improve quality of life for people with RA.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
118

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosed with Rheumatoid Arthritis according to American College of Rheumatology criteria
  • Age 18-65 years
  • Both genders eligible
  • Disease duration of at least 6 months
  • Stable medication regimen for at least 3 months before study
  • Mild to moderate disease activity
  • Able to walk independently with or without assistive devices
  • Willing and able to provide informed consent
  • Agree to participate in the exercise program for 6 weeks
  • Attending AL-Najaf Teaching Hospital for RA management

Exclusion Criteria:

  • Severe cardiovascular disease (unstable angina, recent MI, severe heart failure)
  • Other inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis, lupus)-
  • Recent joint surgery or fracture within the past 6 months
  • Severe osteoporosis with fracture risk
  • Pregnancy
  • Severe cognitive impairment preventing participation
  • Uncontrolled hypertension (BP >180/110 mmHg)
  • Active infection or fever at baseline
  • Severe joint damage preventing exercise participation
  • Participation in another exercise program during the study period
  • Neuromuscular disorders affecting muscle function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Progressive Resistance Training Group

Participants in this group will receive a supervised Progressive Resistance Training (PRT) program for 6 weeks. The intervention includes:

  • Resistance exercises 3 times per week
  • Sessions lasting 45-60 minutes each
  • Exercises targeting major muscle groups of upper and lower extremities
  • Use of resistance bands, light weights, and body weight exercises
  • Progressive intensity starting at 40-50% and increasing to 60-70% of maximum capacity
  • 8-12 repetitions per set, 2-3 sets per exercise
  • Supervised by trained physical therapist at AL-Najaf Teaching Hospital
  • Regular monitoring of pain, fatigue, and disease activity

The program is designed to improve muscle strength in patients with Rheumatoid Arthritis while maintaining safety and avoiding disease exacerbation.
Other: Progressive Resistance Training

Progressive Resistance Training (PRT) program for patients with Rheumatoid Arthritis. The intervention consists of supervised resistance exercises targeting major muscle groups of upper and lower extremities.

Program Details:

  • Duration: 6 weeks
  • Frequency: 3 sessions per week
  • Session duration: 45-60 minutes
  • Setting: AL-Najaf Teaching Hospital

Exercise Components:

  • Warm-up exercises (10 minutes)
  • Resistance training using resistance bands, light weights, and body weight exercises (30-40 minutes)
  • Cool-down and stretching (10 minutes)

Progression Method:

  • Intensity starts at 40-50% of maximum capacity
  • Gradually increases to 60-70% over 6 weeks
  • Repetitions: 8-12 per set
  • Sets: 2-3 sets per exercise
  • Exercises adjusted based on individual tolerance and disease activity

Supervision: Trained physical therapist/nurse supervision with regular monitoring of pain levels, fatigue, and joint swelling.

The program is designed specifically for RA patients with mild to moderate
No Intervention: Control Group - Standard Care

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Muscle Strength from Baseline to 6 Weeks
Time Frame: Baseline and 6 weeks post-intervention
Muscle strength will be measured using manual muscle testing or dynamometer for upper and lower extremities
Baseline and 6 weeks post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Kufa University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 17, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 17, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 23, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 26, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Kufa-2026-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis (RA)

Clinical Trials on Progressive Resistance Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings